Surmodics, Inc. (SRDX)
Market Cap | 470.58M |
Revenue (ttm) | 142.96M |
Net Income (ttm) | 13.50M |
Shares Out | 14.26M |
EPS (ttm) | 0.96 |
PE Ratio | 34.38 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,199 |
Open | 32.61 |
Previous Close | 32.45 |
Day's Range | 32.31 - 33.36 |
52-Week Range | 16.79 - 39.41 |
Beta | 1.04 |
Analysts | Strong Buy |
Price Target | 57.00 (+72.73%) |
Earnings Date | May 1, 2024 |
About SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating... [Read more]
Financial Performance
In 2023, Surmodics's revenue was $132.58 million, an increase of 32.65% compared to the previous year's $99.95 million. Losses were -$1.54 million, -94.37% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SRDX stock is "Strong Buy." The 12-month stock price forecast is $57.0, which is an increase of 72.73% from the latest price.
News
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today report...
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announ...
Surmodics to Participate in Upcoming Investor Conferences in March and April
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the co...
Surmodics to Host Virtual Annual Meeting of Shareholders
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting...
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first q...
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-mont...
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Profess...
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical...
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that fourth ...
Surmodics to Participate in Upcoming Investor Conferences in August
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will participate in upcoming investor conferences.
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #August22023--Surmodics, Inc. (SRDX) announces third quarter of fiscal year 2023 financial results will be released on Wednesday, August 2.
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Angioplasty--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announc...
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #AcuteLimbIschemia--Surmodics announced it has received FDA 510(k) clearance for its Pounce™ LP (Low Profile) Thrombectomy System, a new addition to the Pounce p...
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #JefferiesHealthcareConference--Surmodics today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, at 1:30 p.m. E...
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #ConferenceCall--Surmodics today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year 2...
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #MedicalDevice--The PROWL registry will collect real-world efficacy and safety outcomes data for endovascular interventions using the Pounce thrombectomy system.
Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #ConferenceCall--Surmodics announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26.